Is the FDA Contributing to the Homelessness Crisis?
In a recent op-ed for The Hill, Dr. Jeffrey Singer, and co-author Josh Bloom, PhD, Director of Chemical and Pharmaceutical Research at the American Council on Science and Health, discuss the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program as a barrier contributing to the homelessness crisis among individuals with severe mental illnesses like schizophrenia. Singer notes that two-thirds of homeless individuals suffer from mental health issues, many requiring effective treatments such as clozapine. However, stringent REMS requirements […]